14 June 2021 | Monday | Analysis
Source : Cytivalifescience
Technology transfer is a formalized process for moving the manufacture of a drug from one facility, one scale or one drug life cycle phase to another.
Tech transfer occurs multiple times during the life cycle of a drug as it progresses from lab to commercial production. At each stage, changes in equipment, methods, and materials may require process optimization or redevelopment, and the new production team will need training. Changes in materials or scale can result in process variability, and critical process parameters may need to be optimized, or the entire process may need to be redeveloped.
Whether you are a well-established biopharma company or a small start-up, smooth tech transfer is critical to the success and speed to market of your drug. A successful tech transfer requires diligent planning, proper documentation and procedures, and experienced experts who can guide the process and avoid the pitfalls.
For a large biopharma company, tech transfer may also occur when they want to add capacity by bringing an additional facility on-line, or wish to transfer production to another site, or even to another country.
Small companies that are developing a new drug and do not yet have manufacturing capabilities may wish to work with a contract manufacturing organization (CMO) or contract development manufacturing organization (CDMO). Established companies with many drugs in the pipeline may also turn to CMOs for manufacturing capacity in the pre-clinical and clinical phases. If the drug is approved and enters the market, companies may then wish to transfer manufacture back in-house or to new facilities.
All of these situations involve technology transfer. There are always risks involved: careful planning and documentation, understanding of critical quality attributes, and with attention to detail at every step of the process, are of paramount importance.
Let’s look at a stripped-down model of technology transfer and see what it entails.
Knowledge transfer is the heart of technology transfer. Who will be on the receiving team? Do they have the necessary expertise? What training will be required to complete the tech transfer successfully?
Equipment: It is unlikely that the target facility will have exactly the same equipment and models as the transferring facility. How will these differences affect the process? Will process changes be necessary ?
Raw materials and consumables: If your target facility uses different equipment, are your raw materials and consumables compatible? If you are moving the process to another country, will a secure supply of your media, buffers and resins be available? Are the materials that you are currently using compliant with local regulatory requirements in the new location? If you must substitute, what and how much process re-development will be necessary?
Regulatory considerations: You may need to re-validate your process you are running on different equipment. If you are transferring to a different country, you may need to re-validate not only your process, but also your analytical methods to comply with local regulations.
▻TIP: Remember that tech transfer must also encompass your analytical methods, including characterization testing, release testing and comparability.
A start-up biopharma company at the late research stage or clinical stage will face additional complicating factors.
▻TIP: Ensure that key expertise in the critical process and manufacturing attributes is retained in your organization to help guide tech transfer.
Technology transfer is a significant step along the way to your end goals for your drug or therapy. Make sure these essential factors are in place and aligned with your goals to maximize tech transfer efficiency and success.
Documentation is not an event, but a best practice to be implemented, and referred to, at every step along the way. Templated standard operating procedures and documents, approved by the quality team, will increase the speed, efficiency, effectiveness and quality of technical transfer. Rigorous documentation of deviations along with root cause analysis and corrective/preventative actions will help ensure consistent process execution.
From the technology and bioprocess standpoint, the tech transfer document is the all-important roadmap to implementing your process in the CMO’s environment. It will contain all the information and parameters pertaining to the process and the product, including materials and analytical methods. The more that you have nailed down regarding your process, and your effectiveness in documenting this knowledge, the smoother will be your technology transfer and any ensuing redevelopment.
Since technology transfer is core to the business of a CMO, you can expect your CMO or CDMO to work within the framework of a clearly-defined methodology, documented as a standard operating procedure (SOP). The goal of the technology transfer SOP is to improve the effectiveness, efficiency, quality and compliance of the biomanufacturing technology transfer process. A thorough, reliable tech transfer methodology will go a long way towards ensuring success in both the technical aspects and in building the business relationship.
Expect a technology transfer documented SOP based off a standard methodology and templates, tailored to the specific project. A well-designed SOP will include:
If your tech transfer is to a CMO, the contract with the CMO will be driven by SOP and the technology transfer document, so be sure the SOP is detailed and robust.
Selecting your CMO or CDMO, and crafting your contract with them, is one of the most critical and complex business decisions for your company. You will be sharing your intellectual property with them, and they, in turn, will be creating significant intellectual property as they scale up your drug and continue its development. Be sure to include reputation, as well as capabilities, in your selection criteria. How can you prepare in advance to avoid typical pitfalls?
▻TIP: Hire an experienced expert who can guide you through vendor selection and contracting, who knows what to look for, and what to look out for. It is well worth the investment.
Here are some of the key factors that go into framing your vendor selection and contract.
Planning a successful tech transfer requires understanding what both sides (sending and receiving) have for process and equipment, the differences, and what redevelopment might be required.
▻TIP: Consider the definition of your end-point carefully. While you may be moving from lab to scale-up for pre-clinical production or Phase I trials, is that really your end-point? Choices (e.g. equipment, consumables) at any stage may simplify or add complexity to future tech transfers, scale up and redevelopment activities.
For a small bio-pharma start-up, especially one spun out of a research lab, hiring a consultant with experience in negotiating successful biomanufacturing outsourcing contracts will be a wise investment. Framing all of the aspects of the business relationship, the contract will help set expectations and avoid future pitfalls.
Don’t overlook the intellectual property that will be developed or supplied by the CMO. This may include analytical methods, cell lines that must be licensed, documentation of their process and methods. Should you wish to bring manufacturing in-house, or transfer to a different or additional CMO in the future, will this IP be available to you? What costs will be associated with it?
▻TIP: Remember that when working with a CMO or a CDMO, not only will you be sharing your IP with them, but they, also, may integrate their own IP into the manufacture (and testing) of your drug, as well as potentially develop new IP and you should plan for this eventuality.
The engineering run is a non-GMP trial run which tests your process, equipment and automation to confirm that your process is outlined correctly , as well as confirming that the staff is properly trained to run the process. During an engineering run, your process will be run at scale, or close to at scale, on the CMO equipment prior to transitioning to GMP production. While this can be quite costly, it is worth the expense. During this run, any differences in the process resulting from scale, materials or equipment differences will be exposed. Identified critical process parameters may need to be adjusted. The learnings gained during an engineering run will help drive a lot of risk out of the transition to a GMP manufacturing process. If you go straight into GMP manufacturing and run into any issues, trouble-shooting can be much costlier—in time and money—than the engineering runs.
Technology transfer is a complex undertaking that requires communication, and even collaboration, between the biopharma company and the CMO . Transparency is a key factor, so understand your CMO’s style up front to set clear expectations. For example, what is their policy and preference regarding a “person-on-the-floor” from the client side? Will you be able to go into plant to see how the process is run? This is especially important if you plan to bring the process back in-house.
▻TIP: A relationship is a two-way street. Build trust with clear expectations, communications and transparency.
It may be tempting to think of technology transfer as a “send and receive” process, with the sending organization transferring technology to the receiving organization. It will be more helpful, and set you up for success, to understand tech transfer in the framework of a relationship, whether between the biopharma company and their CMO, or between different teams internally.
When working with a CMO, the tech transfer, while a major milestone, is not just a hand-off—it is the beginning of an ongoing relationship. It is important to establish a strong, cooperative rapport with the CMO’s alliance manager, and to maintain quality oversight on an ongoing basis. Throughout the tech transfer process, you will be defining, establishing and building this relationship. For a start-up or emerging pharma company, this is a bet-your-business prospect.
As in the bioprocess lab, in tech transfer the devil is in the details. Nail down as much as possible up front, but communications and transparency are necessary to deal effectively with the many issues that may arise along the way.